Recently published clinical results suggest patients undergoing Cosentyx treatment for plaque psoriasis have shown marked improvement after four weeks, leading GlobalData to suggest Cosentyx may become the top-selling biologic in the plaque psoriasis market by 2027.
Novartis recently reported results from a pooled analysis of four Phase III clinical trials in moderate-to-severe plaque psoriasis patients treated with Cosentyx (secukinumab).
Psoriasis treatment results
Results show that patients treated with Cosentyx have fewer psoriatic lesions and show improvements in mobility, self-care and a return to regular routines after four weeks of treatment compared to placebo-treated patients.
The trial data suggests Cosentyx may become an attractive option for prescribing physicians and dermatologists, making the treatment a strong contender on the psoriasis market, according to GlobalData.
The pooled analysis of the Erasure, Fixture, Feature and juncture trials combine data from Cosentyx-treated patients who have moderate-to-severe plaque psoriasis.
Patients were randomised and either received 300mg of Cosentyx or placebo at weeks 0, 1, 2, 3, and 4, followed by the same interventions every four weeks.
Prior to starting the study, patients reported issues with mobility, self-care, and usual activities (such as work, study, housework, and family or leisure activities) at baseline, which was recorded by the EQ-5D questionnaire.
The percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities domains were compared at weeks 4, 8, and 12 between patients receiving placebo (n=282) and those receiving 300mg of Cosentyx (n=309).
The pooled results show that the percentage of patients reporting no problems at week 4 was higher with Cosentyx (60.7%) compared to placebo (38.5%).
This trend was also observed at week 8, with Cosentyx at 73.6% versus placebo at 48.1%, and week 12, with Cosentyx at 71.4% versus placebo at 46.6%.
The percentage of patients reporting no problems in self-care at week 4 was higher with Cosentyx (71.4%) compared to placebo (40.9%). Again, this trend was observed again at week 8, with Cosentyx at 79.2% versus placebo at 42.3%, and week 12, with Cosentyx at 87.1% versus placebo at 43.0%. The percentage of patients reporting no problems with usual activities at Week 4 was twice as high with Cosentyx-treated patients (63.8%) compared with placebo-treated patients (31.1%).
This trend was also observed at week 8, with Cosentyx at 74.4% versus placebo at 35.7%, and week 12, with Cosentyx at 82.7% versus placebo at 42.6%.
Cosentyx will be the top-selling biologic in the plaque psoriasis market by 2027, with anticipated sales of $1.4 billion, according to GlobalData’s Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027 report.
GlobalData believes that these clinical trial results could further bolster Novartis’ position in the fiercely competitive plaque psoriasis market and help secure the company’s leadership place.